AtriCure, Inc. $ATRC Position Boosted by Wellington Management Group LLP

Wellington Management Group LLP boosted its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 3.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,495,603 shares of the medical device company’s stock after acquiring an additional 113,048 shares during the quarter. Wellington Management Group LLP owned 6.87% of AtriCure worth $97,807,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ATRC. Geneos Wealth Management Inc. bought a new position in shares of AtriCure in the second quarter worth $37,000. Smartleaf Asset Management LLC raised its stake in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares in the last quarter. Harbor Investment Advisory LLC bought a new stake in shares of AtriCure during the second quarter valued at about $40,000. Allworth Financial LP acquired a new stake in AtriCure in the second quarter worth about $43,000. Finally, Fifth Third Bancorp acquired a new stake in AtriCure in the first quarter worth about $51,000. Institutional investors own 99.11% of the company’s stock.

Insider Transactions at AtriCure

In other AtriCure news, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the sale, the director owned 22,809 shares in the company, valued at approximately $884,989.20. The trade was a 13.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Justin J. Noznesky sold 6,182 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider directly owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 53,616 shares of company stock worth $2,149,994 in the last three months. Insiders own 4.00% of the company’s stock.

AtriCure Price Performance

Shares of NASDAQ:ATRC opened at $48.92 on Wednesday. The company has a market capitalization of $2.49 billion, a PE ratio of 232.96 and a beta of 1.26. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The stock has a fifty day moving average of $38.70 and a 200-day moving average of $32.41. AtriCure, Inc. has a one year low of $25.36 and a one year high of $49.98.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the previous year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts anticipate that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ATRC shares. Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Canaccord Genuity Group upped their price target on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Piper Sandler boosted their target price on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. Finally, BTIG Research boosted their target price on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $49.89.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.